US 12,435,445 B2
Designed ankyrin repeat domains with altered surface residues
Hans Kaspar Binz, Zurich-Schlieren (CH); Johannes Schilling, Ehrendingen (CH); Patrik Forrer, Steinen (CH); Victor Levitsky, Birmensdorf (CH); Natalia Venetz, Zurich (CH); and Marcel Walser, Winterthur (CH)
Assigned to Molecular Partners AG, Zurich-Schlieren (CH)
Filed by MOLECULAR PARTNERS AG, Zurich-Schlieren (CH)
Filed on Jan. 12, 2023, as Appl. No. 18/153,576.
Application 18/153,576 is a continuation of application No. 17/400,471, filed on Aug. 12, 2021, granted, now 11,578,427.
Application 17/400,471 is a continuation of application No. PCT/EP2020/085855, filed on Dec. 11, 2020.
Claims priority of application No. 19215433 (EP), filed on Dec. 11, 2019; application No. 19215434 (EP), filed on Dec. 11, 2019; application No. 19215435 (EP), filed on Dec. 11, 2019; application No. 19215436 (EP), filed on Dec. 11, 2019; application No. 20161059 (EP), filed on Mar. 4, 2020; and application No. 20181234 (EP), filed on Jun. 19, 2020.
Prior Publication US 2023/0340698 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C40B 40/10 (2006.01); A61K 38/00 (2006.01); C07K 14/47 (2006.01)
CPC C40B 40/10 (2013.01) [C07K 14/47 (2013.01); A61K 38/00 (2013.01); C07K 2318/20 (2013.01)] 1 Claim
 
1. A designed ankyrin repeat domain comprising (i) an N-terminal capping module having a glutamine (Q) at a position corresponding to position 8 of SEQ ID NO: 69 and/or a leucine (L), valine (V), isoleucine (I), methionine (M), or alanine (A) at a position corresponding to position 15 of SEQ ID NO: 69, and (ii) a C-terminal capping module having an arginine (R) at a position corresponding to position 14 of SEQ ID NO: 82 and/or a glutamine (Q) at a position corresponding to position 18 of SEQ ID NO: 82.